Bli medlem
Bli medlem

Du är här

2016-09-01

Diamyd Medical AB: Diamyd Medical appoints new head of Clinical Development

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today
announced that Martina Widman, M.Sc. in Mechanical Engineering from
the Royal Institute of Technology in Stockholm and employed in Diamyd
Medical since 2008, as of September 1 succeeds Erika Hillborg as
Director of Clinical Development.

"I warmly thank Erika for her ten years in the company," says Ulf
Hannelius, President and CEO of Diamyd Medical. "Erika built the
clinical operations at Diamyd Medical and under her leadership,
several clinical studies skillfully and cost effectively were
conducted in the US and in Europe. Her efforts have been extremely
important in Diamyd Medical's development."

"It feels sad to leave Diamyd Medical," says Erika Hillborg. "These
years have been amazing and intensely fun and stimulating. Now is the
right time for me to hand over and move on to new projects."

Erika Hillborg is succeeded by Martina Widman, M.Sc. in Mechanical
Engineering from the Royal Institute of Technology in Stockholm with
a specialization in Biomedical Engineering. Martina Widman will be a
member of Diamyd Medical's management team.

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for autoimmune diabetes
through pharmaceutical development and investments in stem cell and
medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based
Therapy (ABT) based on the exclusively licensed GAD-molecule. The
Company's licensed technologies for GABA and Gliadin have also
potential to become key pieces of the puzzle of a future solution to
prevent, treat or cure autoimmune diabetes, and also certain
inflammatory diseases. At this time six clinical studies are ongoing
with Diamyd®. Diamyd Medical is one of the major shareholders in the
stem cell company Cellaviva AB. Stem cells can be expected to be used
in Personalized Regenerative Medicine (PRM), for example for
restoration of beta cell mass in diabetes patients where the
autoimmune component of the disease has been arrested. Diamyd Medical
also has holdings in the medtech company Companion Medical, Inc., San
Diego, USA and in the gene therapy company Periphagen, Inc.,
Pittsburgh, USA.

Diamyd Medical's B-share is traded on Nasdaq Stockholm First North
under the ticker DMYD B. Remium Nordic AB is the Company's Certified
Adviser.

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41. E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26,
Fax: +46 8 661 63 68

E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website:
www.diamyd.com.

This information is information that Diamyd Medical AB is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the
contact person set out above, at 08.30 CET on September 1, 2016.

-----------------------------------------------------------
http://news.cision.com/diamyd-medical-ab/r/diamyd-medical-appoints-new-h...
http://mb.cision.com/Main/6746/2069287/556003.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.